The invention generally relates to the fields of drug delivery and cell capture. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for drug delivery vehicles and/or cell capture.

Disclosed is a magnetic dendrimer compound and a method for preparing the magnetic dendrimer compound, the molecular formula of which is shown in formula (I): Γ(CH.sub.2).sub.3N.sub.(2.sup.n+1.sub.−1)R.sup.1.sub.(2.sup.n+2.sub.−2)R.sup.2.sub.(2.sup.n+1.sub.)(I). In this formula, Γ indicates magnetic particles coated with SiO.sub.2 on a surface thereof, the magnetic particles having been modified by a silane coupling agent; (CH.sub.2).sub.3N.sub.(2.sup.n+1.sub.−1)R.sup.1.sub.(2.sup.n+2.sub.−2) is a dendritic group, and R.sup.2.sub.(2.sup.n+1.sub.) is a lipophilic group, with 0≤n≤100. Further disclosed is a lubricant comprising the magnetic dendrimer compound.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

A modified conjugated diene-based polymer containing: having a weight average molecular weight of 20×10.sup.4 or more and 300×10.sup.4 or less, having a star-branched structure with a conjugated diene-based polymer chain bonded to a modifier residue, wherein the modifier residue has at least 4 silicon atoms, and alkoxy groups and/or hydroxyl groups and the conjugated diene-based polymer chain is bonded to the silicon atom, wherein the number of alkoxy groups and/or hydroxyl groups in the modifier residue is larger than the number of the silicon atoms on average.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.

Provided herein are dendrimer-drug conjugates comprising a dendrimer including a core, building units which are lysine residues or analogues thereof, first terminal groups comprising a drug moiety comprising a Remdesivir nucleoside and a cleavable linker that provides for controlled release of the drug moiety, and second terminal groups comprising a hydrophobic polymeric group. Also provided herein are pharmaceutical compositions comprising the dendrimer-drug conjugates, and method and uses of the dendrimer-drug conjugates in therapy of disorders such as a viral infection, including a Coronavirus (CoV) infection.

A synthesis method includes synthesising copolydendrimers containing heteroatoms from at least two dendrimers as starting precursors.

Compositions may include those of the formula: (I) wherein R1 is an alkyl chain having a carbon number in the range of greater than 40 to 200, R2 is a multiester, R3 is hydrogen, an ion, or an alkyl chain having a carbon number in the range of 1 to 200, m is an integer selected from 0 to 4, and n is an integer selected from the range of 0 to 4, wherein the sum of m and n is 1 or greater. Compositions may include a reaction product of a polyisobutylene-substituted succinic anhydride and a hydroxy-functional dendrimer, wherein the molar ratio of polyisobutylene-substituted succinic anhydride to hydroxy-functional dendrimer is within the range of 10:1 to 30:1. ##STR00001##